Literature DB >> 10195050

Prevalence of HIV-1 among attenders at sexually transmitted disease clinics: analyses according to country of birth.

C A McGarrigle1, A Nicoll.   

Abstract

OBJECTIVES: To determine the importance of world region of birth as a risk factor for HIV-1 infection, the likelihood of having an HIV-1 infection diagnosed and the likelihood of having another coexisting acute sexually transmitted infection (STI) among attenders at genitourinary medicine clinics.
SUBJECTS: Specimens from attenders having routine syphilis serology at 15 sexually transmitted disease clinics in England, Wales, and Northern Ireland participating in the unliked anonymous seroprevalence monitoring programme from 1994 to 1996.
METHODS: Limited data were collected with specimens that were irreversibly unlinked from the source patients before testing for antibodies to HIV-1. Numbers of specimens, the prevalence of HIV-1, the proportions of infections clinically diagnosed, and the presence of coexisting acute STIs were analysed according to world region of birth, sexual orientation, and injecting drug use.
RESULTS: Between 1994 and 1996, 173,075 specimens were collected; 16.9% were from people born outside the United Kingdom. Risk of being HIV-1 positive was significantly higher overall for both men and women born abroad, but this was not the case for those born in south Asia (India, Pakistan, and Bangladesh). Homosexual and bisexual males born abroad were almost twice as likely to be HIV infected as their counterparts born in the United Kingdom. However, homosexual and bisexual men born in the United Kingdom accounted for almost three quarters of the 1174 HIV-1 positive specimens detected. Among 158,728 non-drug injecting heterosexuals the highest prevalence was observed in specimens from those men (4.0%) and women (5.8%) born in sub-Saharan Africa. The 6991 heterosexual men and women born in other European countries were also more likely to provide HIV-1 positive specimens than UK born heterosexuals. However, 39% of the HIV-1 positive specimens in heterosexuals come from clinic attenders born in the United Kingdom. Heterosexual males were generally less likely to have their infection diagnosed than females. There were 182 attendances (mostly from London clinics) non-drug injecting heterosexual men and women who were infected with both HIV-1 and an acute sexually transmitted infection; only 12% of whom had had their HIV-1 infection diagnosed.
CONCLUSION: Among most people attending genitourinary medicine clinics, being born abroad is associated with an increased likelihood for HIV-1 infection. HIV-1 infected heterosexuals, of whom 46% are people from sub-Saharan Africa, are unlikely to have their infection clinically diagnosed and thus are unable to obtain appropriate treatment. The presence of HIV-1 infected heterosexual men and women with acute STI represents a potential source of heterosexual HIV transmission both for those born in the United Kingdom and born abroad.

Entities:  

Mesh:

Year:  1998        PMID: 10195050      PMCID: PMC1758154          DOI: 10.1136/sti.74.6.415

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  8 in total

1.  HIV and AIDS, other sexually transmitted diseases, and tuberculosis in ethnic minorities in United Kingdom: is surveillance serving its purpose?

Authors:  K M De Cock; N Low
Journal:  BMJ       Date:  1997-06-14

2.  Sexually transmitted diseases among foreigners in Italy. Migration Medicine Study Group.

Authors:  B Suligoi; M Giuliani
Journal:  Epidemiol Infect       Date:  1997-06       Impact factor: 2.451

Review 3.  Is research into ethnicity and health racist, unsound, or important science?

Authors:  R Bhopal
Journal:  BMJ       Date:  1997-06-14

4.  AIDS and HIV infection acquired heterosexually.

Authors:  C M Garrigle; V Gilbart; A Nicoll
Journal:  Commun Dis Rep CDR Rev       Date:  1997-08-22

5.  Gonorrhoea in inner London: results of a cross sectional study.

Authors:  N Low; G Daker-White; D Barlow; A L Pozniak
Journal:  BMJ       Date:  1997-06-14

6.  Prevalence of HIV-1 infection among heterosexual men and women attending genitourinary clinics in Scotland: unlinked anonymous testing.

Authors:  G Scott; D Goldberg; M Weir; S Cameron; J Peutherer; D Carrington; E Follett; G Leadbetter; A Scoular
Journal:  BMJ       Date:  1997-11-15

7.  Continuing transmission of sexually transmitted diseases among patients infected with HIV-1 attending genitourinary medicine clinics in England and Wales.

Authors:  M A Catchpole; D E Mercey; A Nicoll; P A Rogers; I Simms; J Newham; A Mahoney; J V Parry; C Joyce; O N Gill
Journal:  BMJ       Date:  1996-03-02

8.  Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial.

Authors:  H Grosskurth; F Mosha; J Todd; E Mwijarubi; A Klokke; K Senkoro; P Mayaud; J Changalucha; A Nicoll; G ka-Gina
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

  8 in total
  4 in total

1.  HIV prevalence among foreign- and US-born clients of public STD clinics.

Authors:  Nina T Harawa; Trista A Bingham; Susan D Cochran; Sander Greenland; William E Cunningham
Journal:  Am J Public Health       Date:  2002-12       Impact factor: 9.308

2.  Screening for HIV infection in genitourinary medicine clinics: a lost opportunity? British Co-operative Clinical Group.

Authors: 
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

3.  Trends in undiagnosed HIV-1 infection among attenders at genitourinary medicine clinics, England, Wales, and Northern Ireland: 1990-6.

Authors:  I Simms; P Rogers; M Catchpole; C A McGarrigle; A Nicoll
Journal:  Sex Transm Infect       Date:  1999-10       Impact factor: 3.519

4.  Estimating adult HIV prevalence in the UK in 2003: the direct method of estimation.

Authors:  C A McGarrigle; S Cliffe; A J Copas; C H Mercer; D DeAngelis; K A Fenton; B G Evans; A M Johnson; O N Gill
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.